Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 349

1.

New biomedical polymer targeting E-selectin to reduce atherosclerosis.

Park K.

J Control Release. 2018 Oct 28;288:277. doi: 10.1016/j.jconrel.2018.09.023. No abstract available.

PMID:
30290920
2.

Impact of anti-PEG antibodies on PEGylated nanoparticles fate in vivo.

Park K.

J Control Release. 2018 Oct 10;287:257. doi: 10.1016/j.jconrel.2018.09.014. No abstract available.

PMID:
30243349
3.

Quantitative non-invasive imaging of target engagement in small animals.

Park K.

J Control Release. 2018 Sep 28;286:485. doi: 10.1016/j.jconrel.2018.08.041. No abstract available.

PMID:
30213377
4.

Triggered delivery of sequestered siRNA to the heart.

Park K.

J Control Release. 2018 Sep 10;285:258. doi: 10.1016/j.jconrel.2018.08.009. No abstract available.

PMID:
30121117
5.

Enhanced treatment of lung cancer by metronomic therapy with oral pemetrexed.

Park K.

J Control Release. 2018 Aug 28;284:250-251. doi: 10.1016/j.jconrel.2018.07.040. No abstract available.

PMID:
30097256
6.

Thermo-responsive polypeptides and micromechanical machines for sustained delivery to the posterior eye.

Park K.

J Control Release. 2018 Aug 10;283:291. doi: 10.1016/j.jconrel.2018.06.034. No abstract available.

PMID:
29980276
7.

Baseline Biomechanical Properties of Epithelia prior to Tissue Expansion in Dogs.

Bowling J, Davidson DD, Tholpady SS, Park K, Eckert GJ, Katona T, Chu TG, Barco CT.

Plast Reconstr Surg Glob Open. 2018 May 14;6(5):e1773. doi: 10.1097/GOX.0000000000001773. eCollection 2018 May.

8.

Combined therapy of imatinib and an anti-CTLA4 immune-checkpoint inhibitor.

Park K.

J Control Release. 2018 Jul 10;281:196. doi: 10.1016/j.jconrel.2018.06.011. No abstract available.

PMID:
29903547
9.

Enhanced bacterial cancer therapy with hydroxychloroquine liposomes.

Park K.

J Control Release. 2018 Jun 28;280:124. doi: 10.1016/j.jconrel.2018.05.028. No abstract available.

PMID:
29880282
10.

3D mesoscopic fluorescence tomography for photoimmunotherapy monitoring in vivo.

Park K.

J Control Release. 2018 Jun 10;279:355. doi: 10.1016/j.jconrel.2018.05.017. No abstract available.

PMID:
29804593
11.

Functional recovery in spinal cord injury using mesenchymal stem cells.

Park K.

J Control Release. 2018 May 28;278:159. doi: 10.1016/j.jconrel.2018.04.044. No abstract available.

PMID:
29747959
12.

Implants attenuating vaginal T lymphocyte activation and inflammation.

Park K.

J Control Release. 2018 May 10;277:183. doi: 10.1016/j.jconrel.2018.04.008. No abstract available.

PMID:
29678269
13.

Microchamber arrays for controlled NIR laser mediated drug delivery to single cells.

Park K.

J Control Release. 2018 Apr 28;276:168. doi: 10.1016/j.jconrel.2018.03.029. No abstract available.

PMID:
29626947
14.

Enhanced immune responses by co-adsorption of liposomal adjuvant formulations to the aluminum-antigen complex.

Park K.

J Control Release. 2018 Apr 10;275:269. doi: 10.1016/j.jconrel.2018.03.017. No abstract available.

PMID:
29599029
15.

Prevention of intimal hyperplasia by immobilized all-trans retinoic acid.

Park K.

J Control Release. 2018 Mar 28;274:118. doi: 10.1016/j.jconrel.2018.02.035. No abstract available.

PMID:
29526191
16.

In utero gene delivery to spinal cord motor neurons.

Park K.

J Control Release. 2018 Mar 10;273:184. doi: 10.1016/j.jconrel.2018.02.022. No abstract available.

PMID:
29499897
17.

Size- and site-dependent distribution of therapeutic proteins into thoracic lymph: Cover Story.

Park K.

J Control Release. 2018 Feb 28;272:182. doi: 10.1016/j.jconrel.2018.02.002. No abstract available.

PMID:
29472065
18.

Absorption of orally administered ultrafine drug particles.

Park K.

J Control Release. 2018 Jan 28;270:304. doi: 10.1016/j.jconrel.2018.01.007. No abstract available.

PMID:
29428059
19.

Treating resistant tumors using HER3-targeted nanobiologics.

Park K.

J Control Release. 2018 Feb 10;271:166. doi: 10.1016/j.jconrel.2018.01.025. No abstract available.

PMID:
29422137
20.

Liquid crystalline drug delivery vehicles for oral and IV/subcutaneous administration of poorly soluble (and soluble) drugs.

Otte A, Soh BK, Yoon G, Park K.

Int J Pharm. 2018 Mar 25;539(1-2):175-183. doi: 10.1016/j.ijpharm.2018.01.037. Epub 2018 Jan 31. Review.

PMID:
29371020

Supplemental Content

Loading ...
Support Center